J.P. Morgan Thinks Moderna Inc’s Stock is Going to Recover

By Carrie Williams

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Moderna Inc (MRNAResearch Report) on August 7 and set a price target of $24. The company’s shares closed on Friday at $13.33, close to its 52-week low of $11.54.

According to TipRanks.com, Kasimov is a 4-star analyst with an average return of 2.9% and a 44.4% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., BioMarin Pharmaceutical Inc., and ACADIA Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Moderna Inc with a $32.50 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $29.79 and a one-year low of $11.54. Currently, Moderna Inc has an average volume of 1.37M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.